AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAIA
  4. [8-K] MAIA Biotechnology, Inc. Reports Material Event

[8-K] MAIA Biotechnology, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source:

Stock MAIA logo
MAIA Biotechnology Inc.

NYSE:MAIA

MAIA Rankings

#5251 Ranked by Market Cap
N/A Ranked by Dividends

MAIA Latest News

Aug 13, 2025
MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
Jul 28, 2025
MAIA Biotechnology Receives FDA’s Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
Jul 17, 2025
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
Jul 9, 2025
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
Jul 1, 2025
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

MAIA Latest SEC Filings

Aug 13, 2025
[8-K] MAIA Biotechnology, Inc. Reports Material Event
Aug 11, 2025
[10-Q] MAIA Biotechnology, Inc. Quarterly Earnings Report
Jul 28, 2025
[8-K] MAIA Biotechnology, Inc. Reports Material Event
Jul 9, 2025
[8-K] MAIA Biotechnology, Inc. Reports Material Event
Jul 2, 2025
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity

MAIA Stock Data

49.23M
23.22M
23.33%
4.06%
1.32%
Biotechnology
Pharmaceutical Preparations
United States
CHICAGO